PHARMACOKINETICS AND PLASMA-PROTEIN BINDING OF BRB-I-28, A NOVEL ANTIARRHYTHMIC AGENT, IN DOGS

被引：4

作者：

CHEN, CL ^{[1
]}

SANGIAH, S ^{[1
]}

RODER, JD ^{[1
]}

CHEN, H ^{[1
]}

BERLIN, KD ^{[1
]}

GARRISON, GL ^{[1
]}

SCHERLAG, BJ ^{[1
]}

LAZZARA, R ^{[1
]}

PATTERSON, E ^{[1
]}

机构：

[1] OKLAHOMA STATE UNIV,COLL VET MED,DEPT PSYCHOL,STILLWATER,OK 74078

来源：

DRUG INVESTIGATION | 1993年 / 6卷 / 04期

关键词：

D O I：

10.1007/BF03259249

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The pharmacokinetics and plasma protein binding of BRB-I-28, a novel antiarrhythmic agent, were investigated in dogs. The plasma concentration-time profile of BRB-I-28, following an intravenous bolus dose of 10 mg/kg, can be adequately described by a 2-compartment open model. The mean volume of distribution at steady-state (Vd(ss)) was 8.759 L/kg, the mean total systemic clearance (CL) was 1.289 ml/h/kg, and the mean elimination half-life (t1/2beta) was 4.645 hours. Following intravenous administration, approximately 1.85% of the dose was excreted in the urine (0 to 48 hours) as parent drug. Changes in plasma concentrations, after oral administration of BRB-I-28 20 mg/kg, were best described by a 1-compartment open model. BRB-I-28 was rapidly absorbed (t(max) = 1.22 hours and C(max) = 1.59 mg/L) with a rapid elimination rate (t1/2kel = 1.583 hours). Oral bioavailability was estimated to be 44.5%. Only 2.56% of the 20 mg/kg oral dose was excreted via the urine (0 to 48 hours). In vitro binding of BRB-I-28 to plasma protein was 29.7 +/- 10.3% at concentrations of 4 to 16 mg/L. In vivo binding of BRB-I-28 to plasma protein was 24.0 +/- 8.7%. Extensive distribution of BRB-I-28 may be due to its low binding to plasma protein. Low oral bioavailability and limited elimination of free parent BRB-I-28 in urine indicates that BRB-I-28 may undergo extensive metabolism, which may be the reason for its short duration of pharmacological effects.

引用

页码：237 / 243

页数：7

共 19 条

[1]

Akaike H., A new look at the statistical model identification, Institute of Electrical and Electronics Engineers (IEEE) Transactions on Automatic Control, 19, pp. 716-723, (1973)

[2]

Alavi F.K., Clarke C.R., Sangiah S., Berlin K.D., Zisman S.A., Et al., Disposition of BRB-I-28 (7-benzyl-7-aza-3-thiabicy-clo[3.3.1]nonane hydroperchlorate), a novel antiarrhythmic agent, Drug Investigation, 3, pp. 317-323, (1991)

[3]

Bailey B.R., Berlin K.D., Holt E.M., Scherlag B.J., Lazarra R., Et al., Synthesis, conformational analysis, and antiarrhythmic properties of 7-benzyl-3-thia-7-azabicyclo[3.3.1]nonan-9-one, 7-benzyl-3-azabicyclo[3.3.1]nonane hydroperchlorate, and 7-benzyl-9-thia-7-azabicyclo[3.3.1]nonan-9-ol hydroperchlorates and derivatives: single-crystal x-ray diffraction analysis and evidence for chair-chair and chair-boat conformers in the solid state, Journal of Medicinal Chemistry, 27, pp. 758-767, (1984)

[4]

Bourne D.W.A., Boomer, a simulation and modeling program for pharmacokinetic and pharmacodynamic data analysis, Computer Methods and Programs in Biomedicine, 29, pp. 191-195, (1989)

[5]

Boxenbaum H.G., Kiegman S., Elashoff R.M., Statistical estimations in pharmacokinetics, Journal of Pharmacokinetics and Bio-pharmaceutics, 2, pp. 123-148, (1974)

[6]

Chen C.L., Lesseley B.A., Clarke C.R., Roder J.D., Sangiah S., Et al., High-performance liquid Chromatographic determination of BRB-I-28, a novel antiarrhythmic agent, in dog plasma and urine, Journal of Chromatography-Biomedical Applications, 583, pp. 274-279, (1992)

[7]

Chen C.L., Roder J.D., Sangiah S., Chen H., Berlin K.D., Et al., High-performance liquid Chromatographic determination of SAZ-VII-22, a novel antiarrhythmic agent, in dog plasma and urine, Analytical Sciences, 9, pp. 429-431, (1993)

[8]

Chen C.L., Roder J.D., Sangiah S., Chen H., Berlin K.D., Et al., High-performance liquid Chromatographic determination of SAZ-VII-23, a novel antiarrhythmic agent, in dog plasma and urine, Analytical Letters, 26, pp. 1125-1135, (1993)

[9]

Chen C.L., Sangiah S., Patterson E., Berlin K.D., Garrison G.L., Et al., Effects of BRB-I-28, a novel antiarrhythmic agent, and its derivatives on cardiac Na+, K+-ATPase, Mg2+-ATPase activities and contractile force, Research Communications in Chemical Pathology and Pharmacology, 78, pp. 3-16, (1992)

[10]

Fazekaz T., Scherlag B.J., Mabo P., Berlin K.D., Garrison G.L., Et al., The comparative antiarrhythmic and proarrhythmic activity of a 3,7-diheterobicyclo[3.3.1]nonane, BRB-I-28, and lidocaine in the 1-4-day-old infarcted dog heart, Acta Physiologica Hungarica, 81, pp. 297-307, (1993)

← 1 2 →